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Abstract
Purpose The aim of this study was to assess patients’ prefer-
ences for efficacy, safety, and mode of administration in
relation to available bone-targeted agents (BTA) for the pre-
vention of skeletal-related events (SREs) associated with bone
metastases in Europe.
Methods Adults in France (n=159), Germany (n=166), and
the United Kingdom (UK; n=159) with a self-reported phy-
sician diagnosis of bone metastases secondary to a solid
tumour completed an online discrete- choice experiment sur-
vey of ten questions, choosing between pairs of hypothetical
BTA profiles. Profiles were defined by five treatment attri-
butes: delay of first SRE, delay of worsening of pain, annual
risk of osteonecrosis of the jaw (ONJ), annual risk of renal
impairment, and mode of administration. Profiles were gener-
ated using an experimental design with known statistical
properties. A main-effects random parameters logit (RPL)
model was applied to relate participants’ choices to the char-
acteristics of the BTA profiles.
Results The most important treatment attributes for pa-
tients across all three countries were time until first
SRE, annual risk of renal complications and time until
pain worsening. For these attributes, better levels of
outcomes were significantly preferred to worse levels
(p<0.05). A 120-minutes infusion every 4 weeks was
the least preferred mode of administration. Risk of ONJ
was judged by patients in the UK and Germany to be
the least important attribute.
Conclusions Patients consider delaying SREs, avoiding renal
impairment and delaying pain worsening as the most impor-
tant goals to consider when selecting treatment to prevent the
bone complications commonly associated with bone
metastases.
Keywords Patient preference . Bonemetastases . Bone
complications . Bone-targeted agents . Conjoint analysis .
Discrete- choice experiment
Introduction
Bone is one of the most common sites for metastatic
spread in advanced cancer, occurring in 65–75 % of
patients with advanced breast and prostate cancer and
30–40 % of patients with advanced lung, kidney or
thyroid cancer [1]. Bone metastases-associated morbidity
can be debilitating and is often characterised by severe
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pain, reduced health-related quality of life and bone
complications (skeletal-related events, SREs) defined as
pathologic fracture, spinal cord compression or the need
for radiation or surgery to bone. If left untreated, two
thirds of patients with bone metastases will develop a
SRE [2], and on average, they will experience a SRE
every 3–6 months [1].
Bisphosphonates (predominantly zoledronic acid)
were the mainstay of treatment to prevent SREs. Re-
cently, the fully- human anti-RANKL monoclonal anti-
body, denosumab, demonstrated superiority versus zole-
dronic acid in preventing SREs in patients with bone
metastases secondary to solid tumours [3]. Although the
phase 3 head-to-head studies evaluated clinical efficacy
of the two treatments, patient and physician preference
could not be assessed given the double-dummy, double-
blind design. Patient-reported preferences incorporate
multiple aspects of treatment elements from a patient’s
perspective, including, but not limited to, clinical
endpoints.
The primary objective of this study was to quantify
patients’ preferences associated with currently available
bone-targeted agents (BTAs) to prevent SREs in patients
with bone metastases secondary to solid tumours. Best
practices [4] were followed in designing and adminis-
tering a discrete- choice experiment (DCE) to elicit
preferences over attributes associated with each BTA.
Patients and methods
Discrete- choice experiments
DCEs are being increasingly used to quantify prefer-
ences for treatments and health outcomes [4–6] as they
offer a systematic way to elicit trade-offs and quantify
the relative importance that patients and physicians
place on treatment characteristics or outcomes [7].
Treatment-related characteristics or outcomes can be
used in a DCE to describe different aspects of the
healthcare system. The relative value of a treatment to
a particular individual is therefore described as a func-
tion of them [8, 9]. These treatment-related characteris-
tics or outcomes, referred to as ‘attributes’ [10–12], are
assigned levels to define the severity, likelihood, or
timing of each. The premise behind DCEs was devel-
oped using psychology and economic (welfare and con-
sumer) theories combined with statistical methodology.
DCEs were first used in the field of marketing and have
since been extended to health economics.
Table 1 Participant and disease characteristics




Female 46.8 62.0 56.6
Male 53.2 38.0 43.4
Age
<45 years 37.2 58.0 42.8
46–65 years of age 44.2 32.9 37.0
>65 years 18.6 9.1 20.2
Primary cancer types
Breast 36.1 23.2 36.5
Lung 20.9 20.7 13.2
Prostate 14.6 17.7 21.4
Kidney 8.2 7.9 4.4
Colon 6.3 7.9 5.0
Thyroid 2.5 4.3 5.0
Melanoma 1.9 4.3 3.1
Other 9.5 14.0 11.3
Time since primary cancer diagnosis
<2 years 69.1 79.5 67.8
Time since bone metastases diagnosis
<1 year 73.0 67.2 65.4
Among those currently taking
treatment to delay complications
of bone metastases
68.4 75.8 70.9
Oral (pills or tablets) 22.7 32.2 30.8
Intravenously 67.3 46.2 51.5
Subcutaneously 9.1 20.3 13.8
Currently receiving chemotherapy 73.0 68.5 53.5
Among those currently receiving chemotherapy: How is chemotherapy given
Intravenously 80.9 67.3 63.1
Oral (pills and tablets) 17.4 26.5 32.1
Other 1.7 6.2 4.8
Losing ability to move around
affected the patient the most
in the past 2 weeks
30.6 46.7 53.5
Had a complication because of bone
metastases
50.9 57.4 59.5
Severity of worst pain in the past week for any reason
No pain 1.9 1.8 5.7
Mild 9.4 22.4 28.9
Moderate 45.3 50.3 44.7
Severe 43.4 25.5 20.8
Severity of average pain in the past week for any reason
No pain 2.5 3.0 6.3
Mild 19.0 29.9 32.3
Moderate 64.6 51.2 53.2
Severe 13.9 15.9 18.2
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Study sample
Eligible participants were at least 18 years of age from France,
Germany, or the United Kingdom (UK) with a self-reported
physician diagnosis of at least one bone metastasis from a
solid tumour. An online research firm recruited members from
existing panels in these countries and administered the 25-
minute survey (January–February 2013).
The survey and protocols for pretesting and final adminis-
tration were reviewed by the Office of Research Protection
and Ethics at RTI International (the responsible study organi-
sation) and approved by their Institutional Review Board
(IRB).
Survey instrument
DCEs rely on survey instruments to collect the information
to elicit preferences. In addition to the survey, participants
provided demographic information and described disease
and treatment experience to facilitate interpretation of re-
sults. The survey consisted of a series of choices between
hypothetical BTA profiles defined by five treatment attri-
butes: how long the treatment delays the first SRE, how
long the treatment delays a clinically- relevant worsening of
pain (2-point increase in the brief pain inventory worst pain
score), annual treatment-related risk of osteonecrosis of the
jaw (ONJ), annual treatment-related risk of renal impair-
ment, and mode of administration. Product inserts for
available BTAs and the literature were consulted to deter-
mine the treatment attributes, attribute definitions and the
attribute levels included. The levels of the attributes in the
survey were designed to encompass the range observed in
current clinical practice.
Draft survey instruments were pretested using face-to-
face, semi-structured interviews in the United States of
America (USA) to assess clarity and the appropriateness of
the descriptive information, to evaluate the salience of the
attributes and levels, to confirm that no other attributes were
missing and to assess participants’ willingness to accept
trade-offs among BTA treatment attributes. Additional face-
to-face interviews were conducted in Europe (four in France,
four in Germany, and three in the UK) to test translation and
cultural relevance. These data were not included in the study
results as these interviews were used to validate the instru-
ment prior to study start.
An algorithm that maximised the amount of statistical
information obtained from a given number of choice questions
was used to develop an experimental design of 40 choice
questions [13–17]. The experimental design ensured that pref-
erences for all attribute-level combinations were statistically
identifiable. To avoid participant fatigue, the experimental
designwas divided into four versions, each with ten questions.
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Fig. 1 Preference weights for
French patients. The vertical bars
surrounding each mean
preference weight denote the
95 % CI about the point estimate.
If the CIs do not overlap for
adjacent levels in a particular
attribute, the mean estimates are
statistically different from each
other at the 5 % level of
significance. ONJ osteonecrosis
of the jaw
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Participants chose between pairs of hypothetical
BTA profiles (Supplemental Fig. S1), with varying
levels of the attributes (Supplemental Table S2). For
each question, participants indicated the BTA they
would choose if only the two options presented each
time were available. To help patients understand the
choices, a written explanation was provided for each
attribute in the first part of the survey (Supplemental
Table S3).
Statistical analysis
Responses were modelled using a random parameters logit
(RPL) model whereby treatment choice is explained by the
attribute levels of the available treatments and a parameter is
estimated for each attribute level. Parameter estimates reflect
the outcome’s marginal influence on treatment choice [9, 18,
19]. The dependent variable in an RPL model is a dichoto-
mous variable set to be 1 when a participant chooses a
treatment and 0 otherwise. All explanatory variables were
modelled as categorical variables and effects-coded,
reflecting participants’ preference weights relative to the
mean BTA profile in the experimental design. Because the
parameter estimates reflect the outcomes’ marginal influence
on treatment choice, they can be interpreted as relative
preference weights, indicating participants’ intensities of
preference for each attribute level [9, 18, 19]. More preferred
outcomes and features resulted in greater relative preference
weights.
The 95 % confidence interval was calculated and reported
for each preference weight estimate to help determine the
significance of differences in the preferences for attribute
levels. When confidence intervals did not overlap, the mean
estimates were statistically different from each other at the 5%
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Fig. 2 Preference weights for German patients. The vertical bars sur-
rounding each mean preference weight denote the 95 % CI about the
point estimate. If the CIs do not overlap for adjacent levels in a particular
attribute, the mean estimates are statistically different from each other at
the 5 % level of significance. ONJ osteonecrosis of the jaw
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We characterised the differences between preference
weights within an attribute as the relative importance of
treatment-related changes between two levels of the same
attribute. The importance of treatment-related changes was
comparable across attributes. With this in mind, we compared
overall attribute importance by comparing treatment-related
changes that evaluated the least and most preferred level
within each attribute [20, 21]. Data were analysed by country
and were not intended to be pooled.
The secondary endpoint of the study was to estimate the
predicted proportion of participants who would choose given
treatment profiles. This was done using the model results for a
product with characteristics similar to denosumab, zoledronic
acid, clodronate, and pamidronate (Supplemental Table S4).
Other available products (e.g. ibandronic acid) were not spe-
cifically included since their attributes values would fall with-
in the parameters estimated for the products included, thus
allowing extrapolation of results.
Results
Participants
Members of patient panels completed a screening test to
corroborate eligibility. Of the 629 eligible patients, 506
(80.4 %) completed the survey (France, 166; Germany,
175; UK, 165). Twenty-two participants always selected
the same answer, i.e. Medication A or B, and were
excluded from the final sample given that such lack of
variation in response was a strong indication that they
were not paying attention to the questions [21]. Thus,
the final sample of 484 patients included 159 French
patients, 166 German patients and 159 UK patients
(Supplemental Fig. S2). In Germany and the UK, a
large proportion of patients were younger than 45 years
of age (58 and 42.8 %, respectively; Table 1), whereas
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Fig. 3 Preference weights for UK patients. The vertical bars surrounding
eachmean preference weight denote the 95%CI about the point estimate.
If the CIs do not overlap for adjacent levels in a particular attribute, the
mean estimates are statistically different from each other at the 5 % level
of significance. UK United Kingdom, ONJ osteonecrosis of the jaw
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Preference weights
Figures 1, 2, and 3 show estimated preference weights for all
attribute levels for the French, German, and UK patients,
respectively. Across all countries, mean preference weights
were consistent with the natural ordering of the level they
represented in an attribute. Thus, better clinical outcomeswere
preferred to worse clinical outcomes.
Across all countries, the levels for time until first SRE, time
until worsening of pain, and risk of renal impairment followed
the natural order from better clinical outcomes to worse, and
the mean preference weight estimates were statistically differ-
ent from each other. Among French and German patients,
preference weight estimates for no annual risk versus a 1 %
annual risk of ONJ were not statistically different from each
other. In the UK, none of the adjacent levels in annual risk of
ONJ were statistically different.
For French patients, administration via 120-minutes infu-
sion every 4 weeks was statistically significantly less preferred
than an injection or a 15-minutes infusion. Among German
patients, administration via 120-minutes infusion every
4 weeks was the least preferred method of administration
and statistically significantly different from all other adminis-
tration modes. Finally, for the UK patients, administration via
120-minutes infusion was statistically less preferred than a
daily oral tablet and injection.
The most important attributes for patients across all three
countries were time until first SRE, annual risk of renal
complications, and time until pain worsening (Table 2).
Among the French patients, the least important attribute ap-
peared to be the mode of administration and, for the German
and UK patients, it was treatment-related risk of ONJ. Of note,
in all the three countries, patients’ preferences for 8-month
increase in time until SRE and a 3-month improvement in the
delay of pain worsening were statistically significant.
In all the three countries, according to the predicted choice
probabilities for the attributes and levels included in the sur-
vey, the majority of patients would choose a treatment profile
with characteristics similar to denosumab (91.2–94.6 %;
Table 3).
Discussion
Patient’s views and preferences are often given minimal con-
sideration in the selection of treatments they will receive; yet,
in some cases, they endure a high impact on their lives at a
time when they may already feel more vulnerable. It is im-
portant, especially in this palliative setting, that the patient is
seen as a key stakeholder and is actively involved in selecting
the appropriate disease management strategy, incorporating
his/her situation and preferences. Thus, DCEs are important
to assess and understand patients’ priorities in choosing from
available treatment options based on their basic attributes
related to efficacy, safety and mode of administration. DCE
methodology has been applied previously in other therapeutic
areas (i.e. HIV, osteoarthritis, cardiovascular, and hepatitis) in
order to elicit patient preferences and better inform clinical
practice [4, 20, 21]. To our knowledge, this is the first such
patient preference or DCE study in this treatment setting and
thus plays an important role for helping to define future
treatment strategies and fostering a more collaborative ap-
proach between the patient and their physicians.











French patients 91.2 (85.4, 94.9) 3.6 (1.8, 6.3) 5.0 (2.9, 8.5) 0.4 (0.1, 0.9)
German patients 94.6 (90.7, 96.9) 3.0 (1.5, 5.4) 2.3 (1.3, 4.1) 0.2 (0.1, 0.5)
UK patients 91.8 (86.8, 94.9) 3.1 (1.6, 5.3) 5.0 (2.9, 8.1) 0.3 (0.1, 0.7)
UK United Kingdom
Table 2 Relative importance of product characteristics
Relative Importance UK France Germany
1 Time until first SRE Risk of renal impairment Risk of renal impairment
2 Time until pain worsening Time until first SRE Time until first SRE
3 Risk of renal impairment Time until pain worsening Time until pain worsening
4 Mode of administration Risk of ONJ Mode of administration
5 Risk of ONJ Mode of administration Risk of ONJ
ONJ osteonecrosis of the jaw, UK United Kingdom, SRE skeletal-related event
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DCEs have some limitations, and perhaps the most impor-
tant is that preferences are inferred from choices over hypo-
thetical treatment profiles. Although choice questions are
intended to simulate clinical decisions, they do not have the
same clinical or emotional consequences of actual decisions.
Thus, differences can arise between stated and actual choices.
With this in mind, the hypothetical scenarios were prepared to
mimic real-world trade-offs as closely as possible in an effort
to minimise any hypothetical bias. Also, the participant rate
for this study was <5 %, which may have introduced selection
bias. Without data on the characteristics of non-participants
(i.e. those who were not eligible or did not consent to partic-
ipate), it is not possible to determine whether the recruitment
procedure used in this study resulted in any bias.
The results from this study suggest that patients are able to
make informed decisions about currently available treatment
options and that there were generally well-defined preferences
for the efficacy, safety and different modes of administration
associated with them. Patients considered delaying SREs,
avoiding renal impairment and delaying pain worsening as
the most important treatment goals to consider when selecting
treatment to prevent the bone complications associated with
bone metastases, thus confirming that for patients as well as
physicians, clinical endpoints such as avoiding SREs [3] and
pain prevention [22] are the most important treatment goals.
Results suggest that patients in fact place value on differences
of different magnitudes between attribute levels, for example,
3 months of additional delay in pain or 8 months of increased
delay of SREs. Thus, certain differencesmay bemeaningful to
patients although they may not reach the level of ‘clinical
significance’ based on traditional definitions. Because of the
nephrotoxicity associated with chemotherapy and the general
health of patients with advanced cancer, patients may fear that
if they develop renal impairment, then it could prevent them
from receiving full-dose chemotherapy regimens and there-
fore prevent them from an optimal management of their
disease. Considering all of these points, patients are essentially
more frightened by bone complications, the thought of severe
and uncontrollable pain and concerns about renal impairment
than a risk of ONJ. Such patient acceptance may be related to
the fact that today, ONJ is more proactively managed by
primary caregivers and that patients are willing to accept an
increasing risk of ONJ in order to prevent SREs and pain.
For all participants, 120-minutes infusion was the least
preferred mode of administration. Factors, such as additional
contact with the primary caregiver and co-administration of a
BTA with chemotherapy, may influence patient preference
relating to the modes of administration and therefore make
this outcome difficult to interpret. For this study, treatment
attributes were taken from the available prescribing
information/summary of product characteristics for each treat-
ment option. This allowed us to compare across the different
treatment options; however, it did not take into consideration
time spent by patients having additional laboratory tests (i.e.
renal function) prior to receiving an infusion nor did it con-
sider that in the real-world setting, an infusion may take some
time to set up, and, therefore, total drug administration time
may in fact exceed that reported in the product information, as
demonstrated in time andmotion studies in this setting [23]. In
addition, the possibility of home administration of an injection
was not specifically considered nor was it explained that the
injection was subcutaneous and not intravenous. This may
explain why clearer preferences between an injection and a
15-minutes infusion were not seen.
The patient population surveyed here is more representa-
tive of the real-world setting than the clinical trial population,
and it can be considered that these results are reflective of the
real-world setting. In this study, only 25–30 % of patients had
been diagnosed with bone metastases for longer than 1 year.
Thus, it could be considered that their opinion may be con-
servative as they have not yet been living with the long-term
effects of bone complications. Despite this, two-thirds of
patients already reported moderate-to-severe pain, suggesting
that current pain management was suboptimal. This also high-
lights the fact that prevention of pain and pain worsening is a
critical consideration for patients.
Although data were not pooled and there was no formal
analysis between the countries, it is clear that there is a high
consistency between the reported outcomes across all coun-
tries. Of note, no difference was observed between countries
where all products are available versus those where only some
are available. This suggests that this kind of evaluation is
useful and perhaps in the future should be considered by
reimbursement agencies as another critical part of the
decision-making process. Understanding and acknowledge-
ment of what patients consider to be important provides
‘added value’ to the decision-making process and should be
incorporated using robust methods such as this type of study.
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